Clinical trials: Type 1 Diabetes, completed
Diabetes Mellitus Type 2
Bridging the Gap by Transitional Care
The purpose of the study is to evaluate patient adherence with discharge diabetes medications up to 120 days following pharmacist counseling during hospital stay about diabetes self management
- Trial name
- NCT01330121
- Testing
- Pharmacist Counseling
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Cook County Health
Diabetes Mellitus, Type 1, Diabetes Mellitus, Brittle
Diabeloop for Highly Unstable Type 1 Diabetes
Feasibility study, comparing experimental treatment (DBLHU closed-loop system) with reference treatment (Low Glucose Predictive Suspend system) in 7 patients going through a series of N-of-1 trials.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Brittle, Closed-Loop
- Trial name
- DBLHU (NCT04042207)
- Testing
- Low Glucose Predictive Suspend system, DBLHU System
- Where
- 2 sites in France
- Volunteers
- 7 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Type 1 Diabetes
MD Logic Pump Advisor -Pediatric Study
The objective of this feasibility study is to evaluate the efficacy and safety of automated determined Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) using the MD-Logic…
- Trial name
- NCT01308164
- Testing
- MD Logic Pump Advisor
- Where
- 2 sites in Israel, Slovenia
- Volunteers
- 25 people
- Sponsor
- Rabin Medical Center
Diabetes Type 2
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
Twelve smoking and twelve non-smoking subjects with Type 2 Diabetes Mellitus will be enrolled in this study to determine the effect of Technosphere® Insulin Inhalation Powder on insulin in the body during a clamp procedure.
- Trial name
- NCT00934414
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia…
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1
- Trial name
- NCT01781975
- Testing
- Imatinib Mesylate
- Where
- 9 sites in United States, Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp…
- Trial name
- NCT01992588
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
Primary Objective: To compare exposure and activity of SAR341402 to NovoRapid® and NovoLog®. Secondary Objective: To assess the safety and tolerability of SAR341402.
- Trial name
- NCT03202875
- Testing
- SAR341402, Insulin Aspart
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Type 1 Diabetes, Nephropathy, Diabetic
SGLT2 Adjunct in T1D
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
- Trial name
- NCT07591077
- Testing
- Empagliflozin (EMPA)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Ain Shams University
Type 1 Diabetes
Closed Loop Insulin Therapy in Type 1 Diabetics Based on Blood Microdialysis, Online Sensors and an eMPC Algorithm
The EU funded project CLINICIP (Closed Loop Insulin Infusion for Critically Ill Patients) aims to develop a low-risk monitoring and control device which allows maintaining metabolic control in intensive care units.
- Trial name
- NCT00535483
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Type 1
Eversense and Dexcom G5: Efficacy and Accuracy in Type 1 Diabetic Patients
Continuous Glucose Monitoring (CGM) systems improve glycaemic control in type 1 diabetic patients but they have different characteristics that could influence patients' quality of life and glycaemic control.
- Trial name
- NCT03613805
- Testing
- Dexcom G5-Eversense, Eversense-Dexcom G5
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- University of Padova
Diabetic Children
IgE-mediated Allergies Among Type 1 Diabetes Mellitus Children, Single Centre Observational Study
an interviewer-administrated questionnaire was designed to take history of allergy in diabetic child come to outpatient clinic fulfilling inclusion criteria and used to collect data.
- Trial name
- NCT05596656
- Testing
- skin prick test
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Mansoura University Children Hospital
Type 1 Diabetes Mellitus
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting…
- Trial name
- NCT04476472
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes Mellitus
The Effect of Uric Acid Lowering in Type 1 Diabetes
Patients with type 1 diabetes mellitus (T1DM) are at high risk of developing kidney complications potentially leading to end stage renal disease.
- Trial name
- NCT02344602
- Testing
- Febuxostat
- Where
- Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
- Conditions
- Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
- Trial name
- NCT00044395
- Testing
- Ruboxistaurin mesylate
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker
The purpose of this study is to see if the Artificial Pancreas Platform (AP Platform = Cell Phone + Closed Loop Control) can successfully control blood sugar in people with type 1 diabetes mellitus on insulin pump therapy in a…
- Trial name
- NCT01582139
- Testing
- Heart rate informed SSM+HMM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions
The main objective of this study is to determine whether day and night closed-loop insulin delivery for 4 weeks under free living conditions is superior to usual insulin pump therapy in adults with type 1 diabetes and HbA1C<7.5%.
- Trial name
- NCT02727231
- Testing
- Florence D2A or similar closed loop glucose control system, CSII with CGM
- Where
- 2 sites in Austria, United Kingdom
- Volunteers
- 29 people
- Sponsor
- University of Cambridge
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.